Shukra Pharmaceuticals Ltd inks MOU with Borns Medical Robotics Inc., USA

Shukra Pharmaceuticals Limited ("the Company") has entered into a Memorandum of Understanding ("MOU") and received on January 05,2026, with Borns Medical Robotics lnc., USA, a globally recognized company in robotic surgical technologies.

1. Brief Details of the MOU

The MOU sets out the framework for collaboration between the parties to introduce, promote and commercialize next-generation AI-enabled soft-tissue surgical robotic systems across India and select South Asian markets, including Nepal, Bangladesh, Sri Lanka, Maldives and Bhutan, subject to applicable regulatory approvals. The entire work will be executed through Shukra Robotics Pvt. Ltd., a subsidiary of M/s. Shukra Pharmaceuticals Ltd.

2. Strategic Rationale and Scope

Under the proposed collaboration, the parties intend to focus on:

Expanding access to advanced robot-assisted minimally invasive soft-tissue surgeries by leveraging high-precision and stability-driven robotic platforms.

Integration of artificial intelligence and digital surgery workflows to enable standardized procedure pathways and enhanced clinical efficiency.

Strengthening regional healthcare infrastructure through technology transfer, clinician training, and scalable deployment models.

Borns Medical Robotics Inc. will contribute its expertise in surgical robotics platforms and Al-enabled technologies, while the Company will leverage its established presence, regulatory execution capabilities, and healthcare market reach in India and South Asia.

This strategic collaboration aligns with the Company's long-term growth strategy of diversifying into high-value, technology-driven healthcare segments. The proposed association is expected to:

Enhance the Company's consolidate business portfolio and market positioning in advanced medical technologies.

Create new revenue opportunities through commercialization, partnerships with hospitals, and ecosystem development.

Strengthen the Company's brand visibility and competitive advantage in emerging digital healthcare solutions.

Support sustainable long-term value creation for shareholders by participating in a rapidly growing global surgical robotics market.

The MOU is non-binding in nature and outlines the intent of the parties to explore definitive agreements in due course, subject to detailed commercial terms, regulatory approvals, and mutual consent.

Source : Equity Bulls

Keywords

ShukraPharmaceuticals MOU BornsMedicaRoboticsInc